I don't have the exact list you're after, but I understand the big pharma are all sitting on a boatload of cash.
According to this article https://www.barrons.com/articles/big-pharma-mergers-biotech-cash-51651844327 as at May 2022 "the cash balance of the top 20 biopharma companies combined is over US$300 billion". So I'd guess the answer to your question is probably at least half a dozen of them could afford buy Neuren at $100+ a share (and a great deal more) if they wanted to.
Note that even if you don't have all the cash on hand to cover a big deal there are many ways to leverage an offer higher than just your available cash.
I don't have the exact list you're after, but I understand the...
-
- There are more pages in this discussion • 2,154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
0.000(0.00%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 54 | $20.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.87 | 409 | 3 |
View Market Depth
| Last trade - 10.00am 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable